The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Responses to romidepsin in patients with cutaneous T-cell lymphoma (CTCL) with tumors and/or folliculotropic involvement.
Francine M. Foss
Consultant or Advisory Role - Celgene; Eisai; Kyowa Hakko Kirin; Seattle Genetics; Spectrum Pharmaceuticals
Honoraria - Celgene; Spectrum Pharmaceuticals
Research Funding - Celgene
Madeleine Duvic
Consultant or Advisory Role - Actelion (U); Celgene (U); Eisai; Kyowa Hakko Kirin (U)
Research Funding - Actelion; Gloucester Pharmaceuticals
Adam Lerner
No relevant relationships to disclose
Alain Rook
No relevant relationships to disclose
Sean Whittaker
Consultant or Advisory Role - Actelion (U); Millennium
Honoraria - Millennium
Research Funding - Millennium
Ellen J. Kim
No relevant relationships to disclose
Youn H. Kim
Consultant or Advisory Role - Celgene (U)
Research Funding - Celgene